TLDR
- PRN.TO gains after TULSA trial shows better quality-of-life than surgery.
- Profound stock climbs as TULSA preserves penile length in new study data.
- CAPTAIN trial boosts PRN.TO after TULSA beats surgery on key outcomes.
- TULSA study lifts Profound shares with stronger patient outcome results.
- Profound Medical rises after trial highlights TULSA quality-of-life benefits.
Profound Medical Corp. shares traded at C$10.45, up 8.18%, after the company released new CAPTAIN clinical trial data. The findings showed the TULSA Procedure preserved penile length better than robotic radical prostatectomy. The latest results added to previous evidence supporting improved quality-of-life outcomes following treatment.
The company presented the findings during the Society of Robotic Surgery Annual Meeting in Fort Lauderdale. Xiaosong Meng, MD, PhD, delivered the presentation using data from the ongoing Level 1 post-market CAPTAIN randomized controlled trial. The study compared whole-gland TULSA with robotic radical prostatectomy in men with localized intermediate-risk prostate cancer.
Profound Medical Corp., PRN.TO
CAPTAIN trial reports improved quality-of-life outcomes with TULSA
The updated analysis showed no median change in penile length one month after the TULSA Procedure. In comparison, robotic radical prostatectomy resulted in a median penile length reduction of 0.65 centimetres. Statistical analysis confirmed a significant difference between both treatment groups.
Researchers estimated a 0.42-centimetre between-group difference using a mixed-effects model. The study achieved a p-value below 0.001, indicating strong statistical significance. The findings strengthened evidence supporting TULSA as a tissue-preserving treatment option.
The new results also expanded on previously reported CAPTAIN safety outcomes. Earlier data showed that TULSA preserved erectile function and urinary continence better than robotic surgery after six months. The latest findings added another quality-of-life measure favouring the MRI-guided procedure.
Trial design supports long-term comparison with robotic prostate surgery
CAPTAIN is a prospective, multi-centre randomized controlled trial evaluating the safety and effectiveness of TULSA against robotic radical prostatectomy. The study enrolled 211 patients across 23 clinical sites in North America and Europe. That figure exceeded the original enrolment target of 201 participants.
The trial includes men with organ-confined, intermediate-risk prostate cancer carrying Gleason Score 7 disease. Its primary safety endpoint measures preservation of both erectile function and urinary continence one year after treatment. The primary efficacy endpoint evaluates freedom from additional prostate cancer treatment, metastases, or disease-related death over three years.
Researchers also continue to assess several secondary outcomes. These include complication rates, histological failure, biochemical failure, and cost effectiveness. As a result, the study aims to provide a broad comparison between the two treatment approaches.
MRI-guided platform expands Profound Medical’s commercial strategy
Profound Medical develops MRI-guided treatment technologies for prostate disease and other medical conditions. Its flagship TULSA-PRO platform enables incision-free prostate tissue ablation under real-time MRI guidance. Physicians can perform whole-gland, partial-gland, or focal treatments while monitoring therapy throughout the procedure.
The company states that the technology supports personalised treatment while reducing complications commonly associated with surgery or radiation therapy. Those complications often include urinary incontinence and erectile dysfunction. The platform focuses on preserving surrounding healthy structures during treatment.
Profound also markets the Sonalleve system for MRI-guided non-invasive therapy. Sonalleve treats osteoid osteoma, bone metastasis pain, desmoid tumours, uterine fibroids, and adenomyosis in approved markets.The company continues evaluating the platform for abdominal cancer treatment and hyperthermia-based cancer therapies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
